Interested in biotech? Check out these free resources and events, people to follow, podcasts, and more. All my Learning Biotech threads in one 👇

Prof. José Baselga has passed on March 21st Dr.Baselga was an amazing oncologist& researcher who paved the way for many molecular targeted therapies in2017 was awarded the ESMO - Eur. Oncology Lifetime Achievement Award Huge loss for the Oncology Community Our thoughts are with his family

RIP Jose Baselga - an amazing oncologist, scientist and human.

We knew that adagrasib is efficient in KRAS G12C mut #NSCLC Interestingly the north face of lung cancer (KRAS and STK11 comutations) can be surmounted by this drug. OncoAlert #ELCC21 Gʀᴇɢᴏʀʏ Rɪᴇʟʏ

Congratulations team Tango! #spacmerger businesswire.com/news/home/2021…

I wrote this article for my own catharsis. I never expected it to be peer reviewed. When NEJM accepted it, I experienced my first panic attack. 1/ Women in Medicine Women in Oncology AMWA Doctors #WomenInMedicine Chat Women in Academia

This one just kills me! These idiot antivaxxers will try anything to get out of vaccines 😹

Preprint of our work on a novel synthetic lethal target is up on bioRxiv! Tango Therapeutics

Good to see continued declines in cancer mortality and ongoing improved outcomes in lung cancer. We must pay close attention to trends in breast cancer, prostate cancer, and ongoing disparities. Much more work to be done!

Google Betty White .,rose petals Will cascade down your screen and "Thank you for being a friend" will play.

Today, Russia started a full-scale war against Ukraine. We believe in our soldiers and we stay strong. We have to postpone our services till Monday, February 28. We hope you take this short-term disruption with understanding.

If you're attending AACR next month and interested in DNA repair in cancer, check out our poster on targeting BRCA1-mutant tumors with USP1 inhibitors. I had the honor of working on this during my time at Tango Therapeutics and I'm excited that it will see the light of day!

Congrats to Natasha Natasha Emmanuel from Tango Therapeutics Tango Therapeutics on leading this exciting study in Cancer Research on Vrk1 in #GBM #BTSM - appreciate the opportunity to contribute to this exciting new synthetic lethality target! Erin Mulkearns-Hubert, PhD aacrjournals.org/cancerres/arti…

VRK1 is a Synthetic Lethal Target in VRK2-deficient #Glioblastoma. aacrjournals.org/cancerres/arti… #btsm Cancer Research

Excited to share some exciting work on VRK1/2 synthetic lethality in GBM. Led by my close friend and mentor Natasha Emmanuel over at Tango Therapeutics. Lots more to discover in the DepMap data! aacrjournals.org/cancerres/arti…

Incredible data presented by Sapna Patel from S1801 in operable melanoma with neoadjuvant vs. adjuvant pembrolizumab at #ESMO22

Audience applause for this waterfall plot! Neoadjuvant immune checkpoint inhibition should become the soc in locally advanced MMR-deficient colon cancer! #ESMO22

LITESPARK-003: Cabo + Belzu phase II trial in 1L therapy for mRCC. Encouraging activity data for this combination. #ESMO22

If only it was this easy...😂

More exciting research from Tango Therapeutics on the use of #USP1 inhibitors for #BRCAmut tumors